Subependymal giant cell astrocytoma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
| Line 14: | Line 14: | ||
*Subependymal giant cell astrocytoma is a disease that tends to affect the pediatric, adolescent, and young adult population.<ref name="pmid21465222">{{cite journal| author=Campen CJ, Porter BE| title=Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update. | journal=Curr Treat Options Neurol | year= 2011 | volume= 13 | issue= 4 | pages= 380-5 | pmid=21465222 | doi=10.1007/s11940-011-0123-z | pmc=PMC3130084 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21465222 }} </ref><ref name=epidemiologyofsega1>Epidemiology of subependymal giant cell astrocytoma. Dr Bruno Di Muzio and Dr Jeremy Jones et al. Radiopaedia 2015. http://radiopaedia.org/articles/subependymal-giant-cell-astrocytoma. Accessed on November 4, 2015</ref> | *Subependymal giant cell astrocytoma is a disease that tends to affect the pediatric, adolescent, and young adult population.<ref name="pmid21465222">{{cite journal| author=Campen CJ, Porter BE| title=Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update. | journal=Curr Treat Options Neurol | year= 2011 | volume= 13 | issue= 4 | pages= 380-5 | pmid=21465222 | doi=10.1007/s11940-011-0123-z | pmc=PMC3130084 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21465222 }} </ref><ref name=epidemiologyofsega1>Epidemiology of subependymal giant cell astrocytoma. Dr Bruno Di Muzio and Dr Jeremy Jones et al. Radiopaedia 2015. http://radiopaedia.org/articles/subependymal-giant-cell-astrocytoma. Accessed on November 4, 2015</ref> | ||
*The mean age at diagnosis is 13 years.<ref name="NabboutSantos1999">{{cite journal|last1=Nabbout|first1=R|last2=Santos|first2=M|last3=Rolland|first3=Y|last4=Delalande|first4=O|last5=Dulac|first5=O|last6=Chiron|first6=C|title=Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis|journal=Journal of Neurology, Neurosurgery & Psychiatry|volume=66|issue=3|year=1999|pages=370–375|issn=0022-3050|doi=10.1136/jnnp.66.3.370}}</ref> | *The mean age at diagnosis is 13 years.<ref name="NabboutSantos1999">{{cite journal|last1=Nabbout|first1=R|last2=Santos|first2=M|last3=Rolland|first3=Y|last4=Delalande|first4=O|last5=Dulac|first5=O|last6=Chiron|first6=C|title=Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis|journal=Journal of Neurology, Neurosurgery & Psychiatry|volume=66|issue=3|year=1999|pages=370–375|issn=0022-3050|doi=10.1136/jnnp.66.3.370}}</ref> | ||
*Subependymal giant cell astrocytoma | *Subependymal giant cell astrocytoma becomes symptomatic, clinically and pathologically, between 8 to 19 years of age.<ref name="OuyangZhang2014">{{cite journal|last1=Ouyang|first1=Taohui|last2=Zhang|first2=Na|last3=Benjamin|first3=Thomas|last4=Wang|first4=Long|last5=Jiao|first5=Jiantong|last6=Zhao|first6=Yiqing|last7=Chen|first7=Jian|title=Subependymal giant cell astrocytoma: current concepts, management, and future directions|journal=Child's Nervous System|volume=30|issue=4|year=2014|pages=561–570|issn=0256-7040|doi=10.1007/s00381-014-2383-x}}</ref> | ||
==Gender== | ==Gender== | ||
Revision as of 15:26, 5 November 2015
|
Subependymal giant cell astrocytoma Microchapters |
|
Differentiating Subependymal Giant Cell Astrocytoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Subependymal giant cell astrocytoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Subependymal giant cell astrocytoma epidemiology and demographics |
|
FDA on Subependymal giant cell astrocytoma epidemiology and demographics |
|
CDC on Subependymal giant cell astrocytoma epidemiology and demographics |
|
Subependymal giant cell astrocytoma epidemiology and demographics in the news |
|
Blogs on Subependymal giant cell astrocytoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Prevalence
- Approximately 10-20% of patients with tuberous sclerosis develop subependymal giant cell astrocytoma.[1]
Incidence
- The incidence of subependymal giant cell astrocytoma is approximately 2.5 per 100,000 individuals in the United States.[1]
Age
- Subependymal giant cell astrocytoma is a disease that tends to affect the pediatric, adolescent, and young adult population.[2][3]
- The mean age at diagnosis is 13 years.[4]
- Subependymal giant cell astrocytoma becomes symptomatic, clinically and pathologically, between 8 to 19 years of age.[5]
Gender
- Males are more commonly affected with subependymal giant cell astrocytoma than females.[2]
Race
Reference
- ↑ 1.0 1.1 Roth, Jonathan; Roach, E. Steve; Bartels, Ute; Jóźwiak, Sergiusz; Koenig, Mary Kay; Weiner, Howard L.; Franz, David N.; Wang, Henry Z. (2013). "Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012". Pediatric Neurology. 49 (6): 439–444. doi:10.1016/j.pediatrneurol.2013.08.017. ISSN 0887-8994.
- ↑ 2.0 2.1 Campen CJ, Porter BE (2011). "Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update". Curr Treat Options Neurol. 13 (4): 380–5. doi:10.1007/s11940-011-0123-z. PMC 3130084. PMID 21465222.
- ↑ Epidemiology of subependymal giant cell astrocytoma. Dr Bruno Di Muzio and Dr Jeremy Jones et al. Radiopaedia 2015. http://radiopaedia.org/articles/subependymal-giant-cell-astrocytoma. Accessed on November 4, 2015
- ↑ Nabbout, R; Santos, M; Rolland, Y; Delalande, O; Dulac, O; Chiron, C (1999). "Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis". Journal of Neurology, Neurosurgery & Psychiatry. 66 (3): 370–375. doi:10.1136/jnnp.66.3.370. ISSN 0022-3050.
- ↑ Ouyang, Taohui; Zhang, Na; Benjamin, Thomas; Wang, Long; Jiao, Jiantong; Zhao, Yiqing; Chen, Jian (2014). "Subependymal giant cell astrocytoma: current concepts, management, and future directions". Child's Nervous System. 30 (4): 561–570. doi:10.1007/s00381-014-2383-x. ISSN 0256-7040.